Tranexamic acid (TXA) reduces surgical blood loss and alleviates inflammatory response in total hip arthroplasty. However, studies have not identified an optimal regimen. The objective of this study was to identify the most effective regimen of multiple-dose oral TXA in achieving maximum reduction of blood loss and inflammatory response based on pharmacokinetic recommendations. We prospectively studied four multiple-dose regimens (60 patients each) with control group (group A: matching placebo). The four multiple-dose regimens included: 2-g oral TXA 2 hours pre-operatively followed by 1-g oral TXA 3 hours post-operatively (group B), 2-g oral TXA followed by 1-g oral TXA 3 and 7 hours post-operatively (group C), 2-g oral TXA followed by 1-g oral TXA 3, 7 and 11 hours post-operatively (group D) and 2-g oral TXA followed by 1-g oral TXA 3, 7, 11 and 15 hours post-operatively (group E). The primary endpoint was estimated blood loss on post-operative day (POD) 3. Secondary endpoints were thromboelastographic parameters, inflammatory components, function recovery and adverse events. Groups D and E had significantly less blood loss on POD 3, with no significant difference between the two groups. Group E had the most prolonged haemostatic effect, and all thromboelastographic parameters remained within normal ranges. Group E had the lowest levels of inflammatory cytokines and the greatest range of motion. No thromboembolic complications were observed. The post-operative four-dose regimen brings about maximum efficacy in reducing blood loss, alleviating inflammatory response and improving analgaesia and immediate recovery.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1676625DOI Listing

Publication Analysis

Top Keywords

oral txa
36
blood loss
20
txa hours
20
2-g oral
16
1-g oral
16
hours post-operatively
16
post-operatively group
16
inflammatory response
12
group 2-g
12
txa 1-g
12

Similar Publications

Tranexamic Acid is Associated With Reduced Blood Loss and Transfusion Requirement in Pediatric Midface Reconstruction.

J Oral Maxillofac Surg

November 2024

Director, Jaw Deformities Care Program, Attending Surgeon, Division of Plastic and Maxillofacial Surgery, Children's Hospital Los Angeles, Los Angeles, CA; Director, Jaw Deformities Care Program, Attending Surgeon, Division of Plastic and Reconstructive Surgery, Keck School of Medicine of USC, Los Angeles, CA. Electronic address:

Article Synopsis
  • The study investigates the effects of tranexamic acid (TXA) on blood loss and transfusion needs during midface reconstruction surgeries, given the significant risks of bleeding in these procedures.
  • Conducted at Children's Hospital Los Angeles from 2010 to 2023, the retrospective cohort study analyzed data from 80 patients, categorizing them based on whether they received TXA or not.
  • Key outcomes measured included intraoperative blood loss, transfusion requirements, complications, and length of hospital stay, with a focus on determining any statistically significant differences linked to TXA administration.
View Article and Find Full Text PDF
Article Synopsis
  • The study conducted a meta-analysis to assess the effectiveness and safety of tranexamic acid (TXA) during endoscopic sinus surgery by analyzing data from 23 randomized controlled trials involving 1,597 patients.
  • TXA significantly reduced intraoperative blood loss, decreased operating time, and improved surgical field quality and surgeon satisfaction compared to control groups, with no reported thromboembolic events.
  • Despite the positive results, the findings were affected by significant variations in study quality and heterogeneity among the included trials.
View Article and Find Full Text PDF

Melasma is a chronic skin pigmentation disorder, and intradermal injection of tranexamic acid (TXA) is an effective treatment option for melasma with limited comparative efficacy studies. To compare the effectiveness of TXA injections with other treatment modalities for patients with melasma, as measured by Melasma Area and Severity Index (MASI). A total of 17 eligible randomized controlled trials were included in the meta-analysis.

View Article and Find Full Text PDF

Background: Perioperative bleeding is a challenge in rhinoplasty and septoplasty. Tranexamic acid (TXA) may help reduce this, but its effectiveness is unclear. This systematic review and meta-analysis aimed to evaluate TXA's impact on bleeding in these procedures.

View Article and Find Full Text PDF

Background: Tranexamic acid (TXA) can effectively reduce intraoperative blood loss and transfusion rates. However, in spinal surgery, the number of surgical levels can significantly influence intraoperative and postoperative bleeding, particularly among the elderly, contributing to the persistently high rate of transfusion during the perioperative period. To verify the safety and efficacy of different application methods of TXA in elderly patients undergoing transforaminal lumbar interbody fusion (TLIF), a prospective cohort study was conducted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!